Type 1 Diabetes Clinical Trial
Official title:
An Open-label, Single-centre, Randomised, 2-period Cross-over Study to Assess the Efficacy and Safety of 24-hour Closed-loop Glucose Control in Comparison With Conventional Subcutaneous Insulin Pump Treatment Simulating Non-compliant Behaviours in Adolescents With Type 1 Diabetes
The ultimate goal of the investigators ongoing research is the development of a closed-loop
system for insulin delivery, which can help people with type 1 diabetes (T1D) attain a tight
glucose control avoiding the risk of hypoglycaemia. The main components of the system are a
continuous glucose monitor (CGM), an insulin pump and a computer-based 'model-predictive
algorithm', which computes the amount of insulin to be given by the insulin pump according
to the CGM values. In the studies performed thus far the efficacy and safety of closed-loop
glucose control was evaluated both overnight and over a prolonged period of time including
the day-time in children and adolescents with T1D. The results showed that closed-loop
improved control of blood glucose and prevented nocturnal hypoglycaemia, as compared to the
conventional insulin pump therapy.
The objective of the current study is to test the performance of closed-loop further, by
evaluating the system during common non-compliant behaviours in the administration of meal
insulin doses in adolescents with T1D. This will pave the way for a more comprehensive use
of closed loop systems to control glucose levels in T1D under various "real-life mimicking"
common circumstances. The present study adopts an open-label, randomised, 2 period
cross-over design whereby closed-loop insulin therapy will be compared with the conventional
insulin pump therapy in 12 adolescents with T1D.
Participants aged 12 to 18 years will be randomised for two 24 hour studies in a clinical
research facility, during which glucose levels will be controlled by either the
computer-based closed-loop algorithm (intervention arm) or by conventional insulin pump
therapy (control arm). On both occasions, participants will under-estimate and omit the
meal-related insulin dose for the evening-meal and lunch, respectively. The study will take
place at the Wellcome Trust Clinical Research Facility (WTCRF), Cambridge with participants
recruited from paediatric diabetes clinics in England.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
Completed |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
Completed |
NCT02897557 -
Insulet Artificial Pancreas Early Feasibility Study
|
N/A | |
Completed |
NCT02855307 -
Closed-loop Control of Glucose Levels (Artificial Pancreas) During Postprandial Exercise in Adults With Type 1 Diabetes
|
Phase 2 |